| __timestamp | Agios Pharmaceuticals, Inc. | Amneal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 84615000 |
| Thursday, January 1, 2015 | 35992000 | 109679000 |
| Friday, January 1, 2016 | 50714000 | 118757000 |
| Sunday, January 1, 2017 | 71124000 | 109046000 |
| Monday, January 1, 2018 | 114145000 | 230435000 |
| Tuesday, January 1, 2019 | 132034000 | 289598000 |
| Wednesday, January 1, 2020 | 149070000 | 326727000 |
| Friday, January 1, 2021 | 121445000 | 365504000 |
| Saturday, January 1, 2022 | 121673000 | 399700000 |
| Sunday, January 1, 2023 | 119903000 | 429675000 |
| Monday, January 1, 2024 | 156784000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, effective cost management is crucial. Over the past decade, Amneal Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, peaking at approximately $430 million in 2023. This reflects a strategic expansion and investment in operational capabilities. In contrast, Agios Pharmaceuticals maintained a more conservative growth, with SG&A expenses increasing by around 500% over the same period, reaching nearly $120 million in 2023. This indicates a focused approach on streamlined operations. The data highlights the diverse financial strategies within the pharmaceutical industry, offering insights into how companies balance growth with cost efficiency.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Sanofi vs Amneal Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.